Equities research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, Alliance Global Partners initiated coverage on Aptevo Therapeutics in a research report on Monday, October 9th. They set a “buy” rating for the company.
Aptevo Therapeutics Trading Down 2.5 %
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.11). Analysts expect that Aptevo Therapeutics will post -2.37 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of APVO. Bank of New York Mellon Corp bought a new stake in Aptevo Therapeutics during the 1st quarter valued at approximately $152,000. Vanguard Group Inc. boosted its stake in Aptevo Therapeutics by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 16,337 shares during the period. Renaissance Technologies LLC boosted its stake in Aptevo Therapeutics by 18.7% during the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 11,000 shares during the period. Virtu Financial LLC bought a new stake in Aptevo Therapeutics during the 2nd quarter valued at approximately $46,000. Finally, Citadel Advisors LLC bought a new stake in Aptevo Therapeutics during the 3rd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
- Five stocks we like better than Aptevo Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- Institutional activity provides a bottom for gaming stocks
- Investing in Travel Stocks Benefits
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- What is the Hang Seng index?
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.